Naloxone Spray Market Companies
The leading companies in the naloxone spray market are Nasus Pharma Ltd., Sandoz Inc., Teva Pharmaceuticals USA, Inc., Emergent Devices Inc., and others. Expanding the availability of over-the-counter (OTC) products, collaborating with governments and non-governmental organizations for extensive distribution, funding public awareness campaigns, breaking into emerging markets, and creating cost-effective generics are some of the main development strategies for naloxone spray firms. Furthermore, it's becoming more and more crucial to use telemedicine and digital health platforms to provide widespread, real-time access.
List of Key Players in the Market:
- Emergent Devices Inc.
- Teva Pharmaceuticals USA, Inc.
- Harm Reduction Therapeutics, Inc.
- Hikma Pharmaceuticals PLC
- Streamline Pharma Private Limited
- Nasus Pharma Ltd.
- Amphastar Pharmaceuticals, Inc,
- INDIVIOR PLC
- Sandoz Inc.
- Viatris Inc.
- AptarGroup, Inc.
- ABneal Pharmaceuticals LLC
- Amphastar Pharmaceuticals, Inc,
- Padagis
- Botanic Healthcare
Recent News:
- In order to sell KLOXXADO naloxone HCl nasal spray 8 mg in the United States and Canada, Hikma Pharmaceuticals PLC (Hikma), a worldwide pharmaceutical business, has inked an exclusive commercial relationship with Emergent BioSolutions (Emergent), on January 2025. In April 2021, the US Food and Drug Administration (FDA) authorized KLOXXADO for the emergency management of opioid overdose in adults and children who were suspected or confirmed to have had respiratory and/or central nervous system depression. NARCAN Nasal Spray 4 mg, the first over-the-counter naloxone medication authorized by the FDA for the emergency treatment of opioid overdose, is distributed by Emergent.
- According to Emergent BioSolutions Inc. on August 2023, NARCAN Naloxone HCl Nasal Spray 4 mg will be sold online and on store shelves across the country starting in September. More people can respond to an opioid emergency thanks to over-the-counter (OTC) access to NARCAN Nasal Spray, which can save lives and keep communities and loved ones safe. The terrible toll of the pandemic, which is mostly caused by synthetic opioids such as fentanyl, makes increasing access and awareness imperative.
- The New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is administered using the company's exclusive nasal delivery device, has been approved by the U.S. Food and Drug Administration ("FDA"), according to a statement released by Amphastar Pharmaceuticals, Inc., on March 2023. Adult and pediatric patients who exhibit respiratory and/or central nervous system depression as a result of a known or suspected opioid overdose should get immediate therapy with naloxone hydrochloride nasal spray (4 mg).